- cafead   Apr 22, 2024 at 06:22: PM
via As a closely watched readout from Alnylam Pharmaceuticals' Amvuttra in the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM) is expected in a few weeks, experts suggested the RNA silencer may have a hard time challenging a Pfizer med.
article source
article source